Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combining a WT1 Cancer Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Malignant Pleural Mesothelioma: A Phase I Study

Next Previous
Trial Profile

Combining a WT1 Cancer Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Malignant Pleural Mesothelioma: A Phase I Study

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galinpepimut S (Primary) ; Nivolumab (Primary) ; Sargramostim
  • Indications Malignant-mesothelioma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 09 Aug 2024 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
  • 09 Aug 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.
  • 04 Jun 2024 Results (n=10) assessing the tolerability and immunogenicity of GS in combination with nivolumab in patients with previously treated DPMthe tolerability and immunogenicity of GS in combination with nivolumab in patients with previously treated DPM were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top